Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Ruxolitinib (Jakavi®) | ||
|
|
Sacituzumab govitecan | ||
|
Sacubitril/Valsartan (Entresto®) |
RICaD. Transfer to primary care at three months following initiation by Heart Failure specialist supported by a RICaD. |
|
|
|
Sapropterin dihydrochloride (Kuvan) | ||
|
|
Sarilumab | ||
|
|
Secukinumab |
|
|
|
|
Selpercatinib (Retsevmo®) | ||
|
|
Semaglutide (Wegovy®) |
The use of semaglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. The Wegovy® brand of semaglutide is not commercially available yet. |
|
|
|
Siponimod (Mayzent®) | ||
|
|
Sirolimus solution |
New post-transplant |
